Equity Overview
Price & Market Data
Price: $2.61
Daily Change: $0.00 / 0.00%
Daily Range: $2.52 - $2.91
Market Cap: $670,275,328
Daily Volume: 7,314,241
Performance Metrics
1 Week: -8.42%
1 Month: -10.31%
3 Months: -29.46%
6 Months: -10.00%
1 Year: 87.77%
YTD: -29.46%
Company Details
Employees: 294
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.